Playing our part in the future of healthcare systems
Posted by
29-Jun-2012
A global UCB leadership team is just back from Boston, where we represented the company in a variety of high profile forums at the annual BIO International Convention.
The Biotechnology Industry Organization (BIO) is the world’s largest biotechnology organisation providing advocacy, business development, and communications services for more than 1,100 members worldwide. Its members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
Most notably at this year’s convention, our CEO, Roch Doliveux, led a discussion of thought leaders surrounding the critical need for health systems to align incentives – more on that below. And, Mark Bodmer, Vice President - Therapy Area Head for Immunology, joined another BIO panel to discuss corporate strategies for progressing academic innovation.
Our presence was also visible as the patient-centric company that sponsored BIO’s Patient Advocacy Pavilion. In addition, the convention served as an appropriate moment in time for UCB to announce its second research collaboration with Harvard to develop therapies for the treatment of neurodegenerative disease.
“Aligning Incentives – A Prerequisite for Healthcare System Innovation,” the panel discussion led by Dr Doliveux, was well attended and featured prominent figures in the biotechnology industry as panelists, including:
One barrier identified was the lack of comprehensive long-term data collection regarding complex and chronic conditions. Several of the panelists proposed that this type of data may provide a fuller picture of long-term patient outcomes to guide treatment decisions. The panelists talked about the use of this data as rationale for payers to consider a longer view on patient outcomes in reimbursement decisions. There was also robust discussion on reevaluating physician reimbursement models.
After the panel, Dr Doliveux hosted a follow up meeting with UCB US President Greg Duncan and a handful of select industry media to discuss UCB’s perspectives surrounding the importance of aligning incentives across stakeholders. Reporters from The Pink Sheet, Med Ad News, R&D Directions, BioPharm Insight, Scrip Intelligence and Pharmaceutical Executive were on hand with insightful comments and questions. Stay tuned for potential stories that feature UCB’s views from these publications.
The Biotechnology Industry Organization (BIO) is the world’s largest biotechnology organisation providing advocacy, business development, and communications services for more than 1,100 members worldwide. Its members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
Most notably at this year’s convention, our CEO, Roch Doliveux, led a discussion of thought leaders surrounding the critical need for health systems to align incentives – more on that below. And, Mark Bodmer, Vice President - Therapy Area Head for Immunology, joined another BIO panel to discuss corporate strategies for progressing academic innovation.
Our presence was also visible as the patient-centric company that sponsored BIO’s Patient Advocacy Pavilion. In addition, the convention served as an appropriate moment in time for UCB to announce its second research collaboration with Harvard to develop therapies for the treatment of neurodegenerative disease.
“Aligning Incentives – A Prerequisite for Healthcare System Innovation,” the panel discussion led by Dr Doliveux, was well attended and featured prominent figures in the biotechnology industry as panelists, including:
- Kalipso Chalkidou, MD, PhD, Director, NICE International
- William Crown, PhD, President, HEOR and Late Phase Research, OPTUMInsight Life Sciences
- Scott Gottlieb, MD, Resident Fellow, American Enterprise Institute
- Brien Smith, MD, FAAN, Chair of the Board of Directors, Epilepsy Foundation of America.
One barrier identified was the lack of comprehensive long-term data collection regarding complex and chronic conditions. Several of the panelists proposed that this type of data may provide a fuller picture of long-term patient outcomes to guide treatment decisions. The panelists talked about the use of this data as rationale for payers to consider a longer view on patient outcomes in reimbursement decisions. There was also robust discussion on reevaluating physician reimbursement models.
After the panel, Dr Doliveux hosted a follow up meeting with UCB US President Greg Duncan and a handful of select industry media to discuss UCB’s perspectives surrounding the importance of aligning incentives across stakeholders. Reporters from The Pink Sheet, Med Ad News, R&D Directions, BioPharm Insight, Scrip Intelligence and Pharmaceutical Executive were on hand with insightful comments and questions. Stay tuned for potential stories that feature UCB’s views from these publications.
Leave a Comment